Start with the vulnerability
SynLeth begins with a tumor-state dependency—HRD, replication stress, a repair defect, or therapy resistance—not with a target in isolation.
KORVIONIX SYNLETH DDR PLATFORM
Synthetic lethality, designed into the asset.
Korvionix builds small-molecule DDR programs around biomarker-defined cancer dependencies and resistance states. SynLeth co-designs the molecule, tumor-selection logic, and experimental proof needed to create a differentiated oncology asset.
01Vulnerability-first biology
02Molecule + biomarker co-design
03Experiment-defined assets
Our differentiation
SYNLETH
A DDR platform built around conditional cancer vulnerabilities—not target lists.
SynLeth asks where a tumor becomes dependent on a DNA-repair pathway, why that dependency should be druggable, and what experiment could disprove the thesis. That context stays attached from target selection through molecular nomination.
Co-design the asset
Chemistry, selectivity, biomarker logic, resistance strategy, and indication fit are designed as one product thesis rather than sequential workstreams.
Design the disproof
Every program carries the assays, counter-screens, failure thresholds, and stop rules needed to challenge the thesis before capital-intensive development.
01
Vulnerability
Define the tumor state and the dependency that creates selective pressure.
02
Mechanism
Connect target engagement to lethality, resistance, and pharmacodynamic logic.
03
Chemistry
Design differentiated, synthesizable series for the relevant target states.
04
Falsification
Challenge selectivity, exposure, safety, biomarker, and IP assumptions.
05
Asset
Nominate a molecule series with a responder thesis and decisive experiments.
Programs
A focused portfolio across DDR vulnerabilities.
Korvionix is building across PAR turnover, replication-stress control, and alternative DNA repair. Each program pairs a differentiated small-molecule thesis with a biomarker-defined tumor context and the experiments needed to test it.
Flagship
PARG
Poly(ADP-ribose) glycohydrolase
Lead program · Computational discovery
Building differentiated PARG inhibitor hypotheses for PARP-inhibitor-resistant and replication-stressed tumor contexts, pairing binding-site design with biomarker and proof-of-mechanism strategy.
- Multi-state pocket design
- PARPi-resistance biology
- HRD & replication stress
Expansion
PKMYT1
Replication-stress checkpoint kinase
Active expansion program · Computational design
Developing a second-generation design strategy for replication-stressed tumor contexts, with early emphasis on chemical differentiation, kinase selectivity, and resistance-aware tumor selection.
- Replication-stress biology
- Kinase selectivity
- Biomarker-linked design
Expansion
POLQ
DNA polymerase theta
Active expansion program · Target and chemistry design
Building a distinct small-molecule program for homologous-recombination-deficient tumor contexts, integrating structural tractability, selectivity, and resistance strategy.
- HRD synthetic lethality
- Structure-led design
- Resistance strategy
Research-stage disclosure
These are computational discovery programs. Molecule-level hypotheses require synthesis, analytical confirmation, and reproducible experimental validation before they can be described as confirmed hits or drug candidates.
What drives SynLeth
Four questions drive every program.
A molecule does not advance because a model scores it highly. It advances only when selective tumor biology, defensible chemistry, and a decisive validation path form one coherent asset thesis.
Who should respond?
Define the genotype, functional state, prior treatment, or resistance mechanism that creates a target dependency—and the biomarker strategy that can identify it.
Why should inhibition be selectively lethal?
Connect genetic dependency, pathway state, target engagement, pharmacodynamic response, and escape routes before a molecule is treated as an asset.
What makes the chemistry defensible?
Integrate receptor states, conserved waters, measured SAR, scaffold white space, selectivity, synthesis, developability, safety, and composition-of-matter opportunity.
What evidence could prove us wrong?
Specify orthogonal assays, counter-screens, liability tests, responder comparisons, and stop criteria so weak theses fail early and visibly.
Platform output
Not a score. An experiment-ready asset package.
SynLeth is designed to hand a scientific or CRO partner a testable program: who the therapy is for, why the chemistry is differentiated, which experiments matter, and what would stop the program.
A defined responder
A target, tumor context, biomarker hypothesis, pharmacodynamic logic, and resistance or combination strategy that belong together.
A defensible series
Ranked, synthesizable designs with binding rationale, scaffold differentiation, selectivity intent, developability risks, and explicit IP questions.
A decisive experiment
Biochemical and cellular confirmation, target engagement, biomarker comparisons, counter-screens, early DMPK, and predeclared go/no-go thresholds.
Company
Focused on DDR assets—not a general-purpose AI platform.
Korvionix is a founder-led computational oncology company in Rockville, Maryland. Its thesis is simple: DDR drugs should be designed together with the tumor context that makes them selectively lethal.
SynLeth directs that work internally; specialized partners execute synthesis, biochemical and cellular assays, DMPK, safety, and translational validation. The result is a lean path from a focused vulnerability thesis to experimental proof.
- Model
- Asset-centric computational biotechnology
- Focus
- Small-molecule DDR oncology
- Location
- Rockville, Maryland
- Legal entity
- Virovance Inc. · Delaware C corporation
Connect
Advance a focused DDR program with us.
Korvionix welcomes accelerator, scientific, infrastructure, CRO, and strategic partnering conversations.
Contact Korvionix